Login to Your Account



Teva-partnered Xenon pain drug fails phase II trial

By Michael Fitzhugh
Staff Writer

Tuesday, June 27, 2017

Xenon Pharmaceuticals Inc. CEO Simon Pimstone said it's going to be hard to ultimately define the reason that the firm's sodium channel Nav1.7 inhibitor, TV-45070, failed to outperform placebo in a phase II postherpetic neuralgia (PHN) trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription